This is from announcement 3/12/2020Hence the capital...

This is from announcement 3/12/2020
Hence the capital raising
Initial investing now for enhanced control & margins later

EU Transition and Trading Update

Transition arrangements for taking back the distribution rights from Mundipharma in the EU are progressing to plan. Progress to date includes the establishment of an EU based legal and corporate structure, contracting of pharmacovigilance and regulatory related service providers and securing operational infrastructure in-market, including importation and logistics capability. The Marketing Authorisations previously held by Mundipharma are being transferred concurrently to allow MVP to assume control of sales and distribution activities on 1 March 2021.

Mr. MacGregor said “The opportunity in the EU remains strong and we’re revisiting our execution strategy, assessing and building on the foundation work done by Mundipharma, including determining where we can deploy a direct or hybrid selling model which brings enhanced control and margin. Europe will be the primary focus of MVP over the coming year.”